NewsWednesday, 28 Jan 2026Help us raise $3,000 to support Glaucoma NZ
We’re taking part in Round the Bays Auckland 2026 to help raise essential funds for the important work of Glaucoma New Zealand.
Auckland Eye is proud to be the first centre in New Zealand participating in the Phase 3 CoMpass clinical trial for small choroidal melanoma and indeterminate lesions (early choroidal melanoma).
The trial is investigating a novel treatment, belzupacap sarotalocan (also known as bel-sar) for early choroidal melanoma, designed to provide a potential vision-preserving alternative to current approaches—most notably radiation therapy, can be associated with significant complications including vision loss, and enucleation (surgical removal of the eye).
It has been more than 30 years since a randomised trial in ocular oncology was conducted in New Zealand, making this milestone particularly significant.
Our sincere thanks to Dr Riyaz Bhikoo, Dr Peter Hadden, Claire Arandjus, Jas Walia, Alice Noone, and our dedicated research team for their commitment in bringing this potential opportunity to eligible patients at Auckland Eye.
For more information, please visit: www.compasspatients.com
[approved by Southern Health & Disability Committee 03Sep25]
News
Monday, 6 Oct 2025
Read More
NewsWednesday, 28 Jan 2026
NewsMonday, 22 Sep 2025i-SIGHT2 Study 2025
Auckland Eye has become the very first site worldwide to recruit and treat a patient in the i-SIGHT2 study.
NewsMonday, 28 Jul 2025Auckland Eye Welcomes Cornea and Anterior Segment Specialist Dr Bia Kim
Auckland Eye is pleased to welcome Dr Bia Kim, a highly trained Cornea and Anterior Segment Specialist, to our team.
